Author

A. Curti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Assay:flow cytometry· 2

Frequent Co-Authors

B. Bassani· 3 shared C. Chiodoni· 3 shared C. Tripodo· 3 shared L. Botti· 3 shared M. Ciciarello· 3 shared M. P. Colombo· 3 shared P. Portararo· 3 shared S. Sangaletti· 3 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

B. Bassani

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

ZEB1 shapes AML immunological niches suppressing CD8 T-cell activity while fostering Th17 cell expansion.

B. Bassani, G. Simonetti, V. Cancila, M. Ciciarello, A. Piva, C. Chiodoni, D. Lecis, A. Gulino, E. Fonzi, L. Botti, P. Portararo, M. Costanza, J. Schwaller, A. Tzankov, M. Ponzoni, , S. Sangaletti

This study shows ZEB1 in AML suppresses CD8 T-cells and promotes Th17 cells, contributing to immune suppression and tumor progression.

bioRxiv · Jul 8, 2023Immunology

MAT2A inhibition in AML unveils therapeutic potential of combining DNA demethylating agents with UPR targeting

K. Zeka, A. V. Taylor, R. Samarista, D. Ragusa, C.-W. Suen, O. W. Cyran, A. F. Domingues, E. Meduri, B. J. Huntly, D. Forte, A. Curti, C. Pina

The paper shows that combining DNA demethylating agents with UPR targeting improves AML cell suppression beyond single-agent therapies.

bioRxiv · Jun 5, 2023 · PreprintCancer Biology

Neutrophil extracellular traps arm DC vaccination against NPM-mutant myeloproliferation

C. Tripodo, B. Bassani, E. Jachetti, V. Cancila, C. Chiodoni, P. Portararo, L. Botti, C. Vaenti, M. Perrone, M. Ponzoni, P. Comoli, A. Curti, M. P. Colombo, S. Sangaletti

This study demonstrates that neutrophil extracellular traps (NETs) loaded with mutant NPMc+ can be used as a vaccine to treat NPMc-driven myeloproliferation by inducing CD8+ T cell responses and reducing leukemic expansion.

bioRxiv · May 19, 2021Immunology

CD40 provides immune privilege to the bone marrow hematopoietic niche

B. Bassani, A. Gulino, P. Portararo, L. Botti, B. Cappetti, C. Chiodoni, N. Bolli, M. Ciciarello, K. Joehrens, I. Anagnostopoulos, I.-K. Na, A. Curti, C. Tripodo, M. P. Colombo, S. Sangaletti

This study shows that CD40 on bone marrow mesenchymal stem cells (BM-MSCs) promotes immune tolerance and prevents graft-versus-host disease by regulating Treg function and B-cell development.

bioRxiv · Aug 10, 2020 · PreprintImmunology

TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia

C. Lai, J. Vadakekolathu, S. Reeder, S. E. Church, T. Hood, I. Aldoss, J. Godwin, M. J. Wieduwilt, M. Arellano, J. Muth, F. Ravandi, K. Sweet, H. Altmann, G. A. Foulds, F. Stolzel, , S. Rutella

This paper shows TP53 mutations in AML are linked to immune features and improved response to flotetuzumab immunotherapy.

bioRxiv · Feb 28, 2020 · PreprintImmunology